Buy Lumigan Eye Drops
What Lumigan eye drops are?
Lumigan eye drops are designed for the treatment of ocular hypertension and open angle glaucoma. The effects of Lumigan eye drops are based on lowering the pressure within the patient’s eyeball, which is normally maintained by the liquid that keeps flowing continuously. Increased pressure typical of the conditions Lumigan eye drops are used to treat can be very dangerous unless the pressure is timely relieved. These days, every person can buy Lumigan online if they do not feel like going anywhere. For instance, to buy Lumigan 0.03 you need just a few minutes of time shopping and a few days to get the delivery, which certainly sounds more convenient in most cases. It’s important to get Lumigan drops after talking with a qualified healthcare professional to make sure you do not need to be using Acular eye drops, Alphagan eye drops or Zaditor eye drops instead.
Mechanism of action
The mechanism of action by which Lumigan eye drops reduces intraocular pressure in humans is to increase the outflow of intraocular fluid through the trabecular meshwork and enhance the outflow from the uveoscleral areas of the eye. The reduction in intraocular pressure begins approximately 4 hours after the first application. The maximum effect is achieved within about 8–12 hours. The duration of the effect is at least 24 hours.
It helps to decrease the increased intraocular pressure in adult patients with chronic open-angle glaucoma and intraocular hypertension (as monotherapy or additional therapy to β-adrenoreceptor blockers).
Lumigan eye drops are used in adults, 1 drop into the affected eye (s) 1 time per day in the evening. The dose should not exceed 1 application 1 time per day. The frequent drug use can reduce the severity of the effect of reducing elevated intraocular pressure.
Hypersensitivity to the active substance or additional components that are part of the drug, including benzalkonium chloride.
In the course of a clinical trial, approximately 38% of patients who were undergoing treatment using Lumigan eye drops, 0.1 mg/ml, had side effects. The most frequent adverse reaction (in 29% of patients) was conjunctival hyperemia (mostly mild and non-inflammatory). About 4% of patients stopped using the drug due to a side effect that arose during the study.
During clinical studies of these eye drops, 0.1 mg/ml, the following adverse reactions were identified. Most of the side effects have a mild form and none were severe.
|Body system||Quantity||Side effects|
|Nervous system||Not often||headache|
|Organs of vision||Very often||conjunctival hyperemia|
|Often||poison hemlock, conjunctival irritation, itching, eyelashes increase|
|Not often||asthenopia, vision impairment, conjunctiva dysfunction, congestion of the conjunctiva, permanent hyperpigmentation, madarosis|
|Digestive tract||Not often||nausea|
|Subcutaneous glands||Often||eyelids reddening, eyelids itching, dermatomelasma, hypertrichiasis|
|The dysfunction of injection site||Often||Itching of the site injection|
Lumigan eye drops should be used for the cases that require this kind of the treatment and a doctor should always be contacted to make sure the right treatment has been chosen. There are cases when you have to particularly careful, especially when you have diabetic retinopathy, blocked retinal vein, dry eyes, congenital glaucoma, closed angle glaucoma, decreased kidney function, inflammatory conditions of the eye, inflammatory glaucoma, the artificial lens in the eye, respiratory disease, cornea, neovascular glaucoma or conjunctivitis. Although due to the method of application Lumigan eye drops are not too likely to interact with other drugs you may be using, talking to your doctor about those is also important. There is a chance Lumigan eye drops may also interact with some other drops you put into your eyes, which is why you should avoid using any other drops or eye remedies without discussing them with your health care provider.
No interaction study was performed. Human interactions are not expected since the systemic concentrations of this substance are extremely low.
Preclinical studies indicate that Lumigan eye drops are biotransformed in the body using any of the numerous enzymes and metabolic pathways. It does not affect the liver enzymes involved in the metabolism of drugs.
In clinical studies, bimatoprost solution in the form of eye drops was used simultaneously with several different ophthalmic blockers of beta-adrenoreceptors (timolol 0.5%) with no signs of interaction.
The simultaneous use of the drug Lumigan and drugs for the treatment of glaucoma, except for topical beta-adrenoreceptor blockers, have not been studied in the course of additional glaucoma therapy.
No cases of drug overdose were reported. When applied topically in the form of eye drops, overdose is unlikely to happen. In case of overdose, supportive and symptomatic therapy is required.